Find us on:    
  HOME  
  ABOUT US  
  RESEARCH & HEALTH  
  BOOKLETS & PAMPHLETS  
  NEWS  
  SUMMER FUNDRAISER  
  PSAs  
 
 
WRI Hospital Partner in Kansas City Plays Key Role in Drug Approval

Cystic Fibrosis patients with the defect G551D mutation may benefit from the FDA's approval of Kalydeco. Kalydeco is the first drug that targets the underlying causes of Cystic Fibrosis. Children’s Mercy Hospital in Kansas City, a partner of WRI, helped trial the drug. For the past seven years, WRI has given $600,000 with 100% of the funds underwiting the drug trial study at Children’s Hospital. Kalydeco represents a major treatment advance for the cystic fibrosis community. In clinical trials patients who took Kalydeco showed:
  • A significant improvement of lung function
  • A significant reduction in sweat chloride to below the diagnostic level for CF
  • Fewer pulmonary exacerbations
  • Patient-reported reduction in respiratory symptoms
  • Improvement in weight gain; and
  • No safety issues

Full FDA Press Release
© 2012 Will Rogers Institute
WRI is a program of the Will Rogers Motion Picture Pioneers Foundation Tax I.D. #15-053351
http://www.frontporchwebsolutions.com/